NeOnc Technologies (NTHI) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OS Therapies (OSTX) has outperformed NeOnc Technologies (NTHI) over the past year, losing 20.6% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($79.8 million vs $77.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTHI | OSTX |
|---|---|---|
| Share price | $2.77 | $1.65 |
| Market cap | $79.79M | $77.23M |
| 1-day change | +9.49% | +1.85% |
| YTD return | -69.41% | +15.71% |
| 1-year return | -79.07% | -20.59% |
| Forward P/E | — | 4.76 |
| EPS (TTM) | $-2.13 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.09 | $2.25 |
| 52-week low | $2.50 | $1.15 |
| Distance from 52-week high | -77.09% | -26.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +513.72% | +415.15% |
| Average volume | 195.17K | 586.70K |
| Shares outstanding | 28.81M | 46.81M |
| Employees | 5 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OSTX has outperformed NTHI by 58.5 percentage points over the past year.
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NTHI vs OSTX FAQ
Which is bigger, NeOnc Technologies or OS Therapies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $79.79M compared with $77.23M for OS Therapies (OSTX).
Which stock has performed better over the past year, NTHI or OSTX?
OSTX returned -20.59% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are NeOnc Technologies and OS Therapies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.